UBS Group’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $541 | Sell |
455
-12,433
| -96% | -$14.8K | ﹤0.01% | 8469 |
|
|
2025
Q1 | $26.2K | Sell |
12,888
-1,329
| -9% | -$2.7K | ﹤0.01% | 6738 |
|
|
2024
Q4 | $85.6K | Buy |
14,217
+8,555
| +151% | +$51.5K | ﹤0.01% | 5755 |
|
|
2024
Q3 | $39.6K | Sell |
5,662
-5,490
| -49% | -$38.4K | ﹤0.01% | 5767 |
|
|
2024
Q2 | $64.7K | Sell |
11,152
-1,593
| -12% | -$9.24K | ﹤0.01% | 5339 |
|
|
2024
Q1 | $91.1K | Buy |
+12,745
| New | +$91.1K | ﹤0.01% | 5113 |
|
|
2023
Q4 | – | Sell |
-102
| Closed | -$975 | – | 8015 |
|
|
2023
Q3 | $975 | Sell |
102
-9,678
| -99% | -$92.5K | ﹤0.01% | 7050 |
|
|
2023
Q2 | $127K | Buy |
9,780
+4,384
| +81% | +$56.8K | ﹤0.01% | 4782 |
|
|
2023
Q1 | $68.5K | Buy |
5,396
+648
| +14% | +$8.22K | ﹤0.01% | 5128 |
|
|
2022
Q4 | $54.7K | Buy |
+4,748
| New | +$54.7K | ﹤0.01% | 5531 |
|